India DCC Tightens Curbs on GLP-1 Drug Advertising
India's Drugs Consultative Committee flagged surrogate and misleading advertising of GLP-1 obesity drugs like Semaglutide at its 68th meeting, recommending tighter enforcement by State Drug Controllers. The move follows a March 10, 2026, CDSCO advisory prohibiting public-directed promotion of prescription-only GLP-1